Preoperative CA 19-9 levels and tumor resectabilty and survival rates in pancreatic cancer

CA 19-9 (U/mL)	Number of patients	Resectability (%)	R0 resection (%)	Survival after resection		Survival if unresectable
CA 19-9 (U/mL)	Number of patients	Resectability (%)	R0 resection (%)	5-year (%)	Median (months)	Median (months)
<5	99	73.7	48.6	21.9	26.8	10.1
5 to <37	281	79.7	52.7	27.2	28.5	9.1
37 to <100	216	83.3	46.9	19.1	26.9	8.6
100 to <250	247	82.2	42.1	16.8	22.5	5.4
250 to <500	204	72.1	37.0	8.3	20.1	9.2
500 to <1000	184	67.4	44.7	7.0	15.4	8.9
1000 to <2000	126	61.1	32.5	0.0	12.0	6.8
2000 to <4000	92	45.7	31.0	0.0	12.3	6.2
≥4000	94	38.3	27.8	0.0	14.4	7.2
		p<0.0001	p = 0.0009		p<0.0001	p = 0.065

Preoperative CA 19-9 levels were available for 1106 patients with resectable and for 437 patients with unresectable pancreatic adenocarcinomas. The R0 resection rate was calculated by using resectable patients only. Including all patients with CA 19-9 ≥1000 U/mL (resectable and unresectable), a R0 resection was achieved in only 15.4% of this group. Starting in 2005, histopathologic reporting applied the refined resection margin evaluation, as detailed in a prior report (Hartwig W, Hackert T, Hinz U, et al. Pancreatic cancer surgery in the new millennium: better prediction of outcome. Ann Surg. 2011; 254:311-9).

Reproduced by permission from: Springer. Annals of Surgical Oncology. Hartwig W, Strobel O, Hinz U, et al. CA19-9 in potentially resectable pancreatic cancer: Perspective to adjust surgical and perioperative therapy. Ann Surg Oncol 2013; 20:2188. Copyright © 2013. https://link.springer.com/journal/10434.

Graphic 91517 Version 8.0

خرید پکیج

Preoperative CA 19-9 levels and tumor resectabilty and survival rates in pancreatic cancer